The Gut Week Summit 2019


From 5 to 8 of November 2019, Barcelona, Spain will host The Gut Week Summit 2019. This 2nd Annual event brings together leading scientists, physicians, and senior leaders to explore the potential insights into the Microbiota–Gut–Brain Axis, the Human Microbiome Market that exhibits significant potential in the near future and skin’s microbiome that has the potential to revolutionize the beauty and personal care industry.

40+ expert speakers, 40+ case studies demonstrating disease causation of the gut-brain axis and Skin Microbiome

The ability of gut microbiota to communicate with the brain is emerging as an exciting concept in health and disease. Mounting evidence, mostly from rodent studies, suggests that gut microbes help shape normal neural development, brain biochemistry, and behaviour.

The Gut Week Summit 2019 is set to be the “must-attend” meeting for anyone interested in unlocking the potential of the Human Microbiome, and translating it into safe, effective and commercially viable therapeutics.


The Gut Week Summit 2019 will be dedicated to help large pharma, biotech, academics and clinicians exploring and understand the Human Microbiome Market, GBA in demonstrating disease causation and changing perceptions of bacteria in the Skin Microbiome. Over the last decade, the microbiome has become one of the trendiest areas of biology, and the research has made clear that the microbiome is fundamental to overall health.



5-6 NOV 2019

  • The influence of the intestinal microbiome on vaccine responses
  • Effectively understand and manipulate the Gut-Brain Axis
  • Learn about the microbiota and their metabolites and neurotransmitters production
  • Influence of the microbiota on vaccine effectiveness
  • Discover tools and technologies to help investigate the GBA
  • Build predictive pre-clinical models in the gut-brain axis
  • The importance of the gut–brain axis in emotional, behavioral and development disorders
  • Stress related bowel disease: gut-brain axis in IBD and IBS
  • Develop commercially viable therapeutics and nutritional products
  • Probiotics, prebiotics, synbiotics and psychobiotics

7-8 NOV 2019

  • Skin Disease & Microbiome
  • The impact of environment and age on shaping our individual microbiota
  • The skin microbiome: Current perspectives and future challenges
  • Preservative Free-Formulation, Manufacturing and Packing
  • The Skin Microbiome & Big Data
  • Metabolites & Skin Microbiome
  • The Development and Maintenance of the Skin Barrier
  • Human Skin Microbiome: From metagenomes to therapeutics
  • Commercialization of Microbiome-Based Personal Care
  • Regulation considerations for dermatology & cosmetics
  • Academic-Industry Collaborations


  • 4D Pharma Research
  • Amabiotics
  • AMC
  • Amylgen
  • APC Microbiome Ireland
  • Astel Medica
  • AstraZeneca
  • Biocodex
  • Biose
  • Bloom Science
  • Chain Biotech
  • Columbia University Medical Center
  • Danone Produits Frais
  • Exden
  • Finch Therapeutics
  • Greenmed
  • Grenoble Faculty of Medicine & Hospital
  • Holobiome
  • ImmuneBiotech AB
  • Institute of Marine Research
  • Jackson Laboratory
  • Karolinska Institutet
  • Kilee Patchell-Evans Autism
  • Kobiolabs
  • L’Oreal Advanced Research
  • Lallemand Health Solution
  • Lesaffre Human Care
  • LNC Therapeutics
  • Lundbeck
  • Maastricht University
  • MP Healthcare
  • NeribiOm
  • Nestlé
  • Neurosciences Paris Saclay
  • Nicklaus Children’s Hospital
  • Northumbria University
  • Novo Nordisk Foundation
  • Örebro University
  • Pharmabiotic Research
  • PiLeJe
  • PRI: Microbiotic Medicinal Products
  • ProDigest
  • Quay Pharmaceuticals
  • Seventure Partners
  • TargEDys
  • Texas Children’s Microbiome
  • UCB Biopharma
  • UCLA
  • University Novi Sad
  • University of Melbourne
  • University of Michigan
  • Winclove Probiotics




  • Scientific Project Leader
  • Head Search & Evaluation Neuroscience
  • Molecular Toxicology
  • Nutrition & Health
  • Laboratory Director
  • Neuroscientist
  • Modeling and Data Specialist
  • Microbiome and Lipid Biology
  • Genome Editing
  • Business Develoment
  • Associate Research Director
  • Strategy & Business
  • IVD Assay Development
  • Safety Risk Lead
  • Skin & Health
  • Preclinical Group Leader
  • Pharmacovigilance
  • Drug Discovery
  • Research Investigator
  • Regulatory Affairs

CEO and Founder at Persona Biome
President for Pen & Tec Consulting
General Partner at Flagship Pioneering
CEO at LNC Therapeutics
Associate Professor at McMaster University
President & Chief Executive Officer at Metabolon
Founder and Chief Science Officer at Viome
Scientific officer at BioGaia
President at European Scientific League for Probiotics - ESLP 
Science Director Europe at Yakult Europe BV
Ruth Ann Luna
Assistant Professor, Director of Medical Metagenomics in the Texas Children's Microbiome Center
Scientific Director, Advanced Research at L'Oreal
Head of Discovery, Microbiome and Human Health at Chr. Hansen Holding A/S
Associate Professor at University of California, Los Angeles
Chairman of the Board at Lactobio
Associate Professor at University of Gothenburg
Instructor at Texas Children's Microbiome Center & Baylor College of Medicine
Serguei Fetissov
Professor of Physiology at Rouen University and Co-Founder of TargEDys
Shahram Lavasani
Founder and CEO at ImmuneBiotech AB
Professor of Neurogastroenterology at AMC, CoFounder of Gut Research
Senior Lecturer at APC Microbiome Ireland
Assistant Professor at Eastern Washington University
Head of Unit at PHENOMIN-ICS
Neurologist / CEO at Helsinki University Hospital and NeuroInnovation
Chief Business Officer at EnteroBiotix
Vice President Translational Medicine at Pierre Fabre, FR
Director Institute for Applied Molecular Medicine at Universidad San Pablo Madrid
Co-founder and Director at Progetto Microbioma Italiano
CEO at GeneSurge GmbH
Clinician at National University of Singapore
Official Website
Click here

Investors/Academic Pass

Industry Packages

Group Discounts